Tirzepatide is sold under the name Mounjaro to treat type 2 diabetes Shutterstock / Mohammed_Al_Ali A weight-loss drug called tirzepatide has received approval from the US Food and Drug Administration (FDA) for adults who are overweight or have obesity and at least one weight-related condition, such as high blood pressure or type 2 diabetes. In clinical trials, it reduced body weight by an average of almost 21 per cent in people who were overweight or had obesity. “That’s the most weight loss we’ve ever seen with a medication,” says at Weill Cornell Medicine in New York.
“[It is] a magnitude of weight loss that’s equivalent to surgery.” The prescription medication, developed by US pharmaceutical company Lilly, was previously approved under the name Mounjaro for treating . It is now the seventh medication approved for in the US.
Advertisement Read more “With rising rates of obesity, there’s been an increased demand for medications indicated for weight management, and we have faced shortages in the past,” says at NYU Langone Health in New York. Tirzepatide’s approval will increase supply and hopefully , she says. Tirzepatide, sold under the brand name Zepbound, is a once-weekly injection that mimics two hormones: GLP-1 and GIP.
The body naturally produces GIP once we start eating, which increases hunger, and then releases GLP-1 after eating to trigger the sensation of fullness, says Aronne. “For reasons we still don’t understand, when you give [GIP] al.
_1b78fec41a5143afb6e7b9ad317023d2-620x480.jpg)
